Tebentafusp Sustains OS Benefit in Previously Untreated, Metastatic Uveal Melanoma
Source: OncLive, November 2023
Paul Nathan, MBBS, PhD, MRCP, discusses the differences between cutaneous melanoma and uveal melanoma that have led to unique unmet needs for patients with the latter malignancy; updated findings from the IMCgp100-202 trial; and how these findings may influence future clinical practice.
The TCR-directed bispecific antibody tebentafusp-tebn (Kimmtrak) maintained a 3-year overall survival (OS) benefit vs immunotherapy or chemotherapy in previously untreated patients with advanced, HLA-A*02:01–positive uveal melanoma, according to Paul Nathan, MBBS, PhD, MRCP.1,2
The phase 3 IMCgp100-202 trial (NCT03070392) investigated tebentafusp vs investigator’s choice of pembrolizumab (Keytruda), ipilimumab (Yervoy), or dacarbazine in patients with previously untreated, advanced, HLA-A*02:01–positive uveal melanoma. At 3 years of follow-up, tebentafusp (n = 252) elicited a median OS of 21.6 months (95% CI, 19.0-24.3) vs 16.9 months (95% CI, 12.9-19.5) with the agents in the comparator arm (n = 126; HR, 0.68; 95% CI, 0.54-0.87).